Insider Selling: Artivion (NYSE:AORT) Insider Sells 6,393 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 6,393 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $44.67, for a total transaction of $285,575.31. Following the transaction, the insider directly owned 198,842 shares in the company, valued at $8,882,272.14. This trade represents a 3.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Artivion Stock Up 0.7%

AORT stock traded up $0.32 during trading on Tuesday, reaching $45.44. 149,362 shares of the stock were exchanged, compared to its average volume of 433,748. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.04. The firm’s 50 day moving average is $42.72 and its 200 day moving average is $36.51. The firm has a market cap of $2.15 billion, a P/E ratio of -108.26 and a beta of 1.65.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on AORT. Wall Street Zen upgraded shares of Artivion from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Stifel Nicolaus lifted their price target on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. JMP Securities increased their price objective on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Finally, Citizens Jmp raised their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Artivion has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Institutional Trading of Artivion

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd lifted its holdings in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the last quarter. MCF Advisors LLC boosted its stake in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after buying an additional 614 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the last quarter. State of Wyoming purchased a new stake in shares of Artivion in the 3rd quarter valued at $80,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Artivion during the 3rd quarter valued at $92,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.